Lone Nørgård Pétersen

Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial

Josep Tabernero, Enrico Mini, Fabien Subtil et al. · The Lancet Oncology · 2014 · 284 citations · Full text

Medicine, Oncology, Pharmacology +14

TAS-102 with or without bevacizumab in patients with chemorefractory metastatic colorectal cancer: an investigator-initiated, open-label, randomised, phase 2 trial

Per Pfeiffer, Mette Yilmaz, Sören Möller et al. · The Lancet Oncology · 2020 · 231 citations

Medicine, Oncology, Pharmacology +10

Persistent DNA damage inhibits S-phase and G2 progression, and results in apoptosis.

David K. Orren, Lone Nørgård Pétersen, Vilhelm A. Bohr · Molecular Biology of the Cell · 1997 · 139 citations

Life Sciences, Cell Biology, Molecular Biology +17

The role of RAD51 in etoposide (VP16) resistance in small cell lung cancer

Lasse Tengbjerg Hansen, Cecilia Lundin, Mogens Spang‐Thomsen et al. · International Journal of Cancer · 2003 · 117 citations · Full text

Medicine, Molecular Biology, Oncology +17

Safety and effectiveness of regorafenib in patients with metastatic colorectal cancer in routine clinical practice in the prospective, observational CORRELATE study

Michel Ducreux, Lone Nørgård Pétersen, Leopold Öhler et al. · European Journal of Cancer · 2019 · 76 citations · Full text

Medicine, Oncology, Pharmacology +16